All News
EULAR 2024 Rheumatology Roundup (6.21.2024)
Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna
Read Article
Camels and psoriatic arthritis - a new treatment link
I am a big fan of animals and wildlife. Whenever I can, I try to wander outdoors to look for our friends big and small in the animal kingdom. If it rains, as often it does in the UK, the latest edition of Planet Earth will do. So, I was naturally attracted to the presentation by Professor Iain McInnes from the University of Glasgow, oral presentation OP0195 at #EULAR2024 where the link between camels and psoriatic arthritis was made.
Read Article
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @Yuz6Yusof https://t.co/eSqOkBGBK2
Dr. John Cush RheumNow ( View Tweet)
PsA Treatment: is Earlier Better?
Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria.
https://t.co/l2M19PwhzP https://t.co/f3TGBVszU4
Dr. John Cush RheumNow ( View Tweet)
Transition from Psoriasis to PsA: Can we Prevent It?
Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria.
https://t.co/MnHG9DgA3H https://t.co/Vht33gWVlC
Dr. John Cush RheumNow ( View Tweet)
EULAR 2024: Tuesday’s Topic Panel (PSA) with RheumNow https://t.co/j4I1bC9ROD
Links:
Dr. John Cush RheumNow ( View Tweet)
Can we prevent psoriatic arthritis?
PsA affects up to 30% of PsO patients. Understanding factors that lead to PsA helps in early interventions. Most PsA patients have preceding PsO.
https://t.co/03H4YrvxMe https://t.co/efUVaccSHn
Dr. John Cush RheumNow ( View Tweet)
Is Izokibep the new kid on the block in PsA?
➡️ IL-17A inhibitor
➡️ Complete resolution of enthesitis at 16w
➡️ Overall good safety data
LBA0005 #EULAR2024 @RheumNow https://t.co/8htPOz9YCG
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH COHORT STUDY- despite having minimal sun 25% increase NMSC TNFis vs other bDMARDs - skin checks ! @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
EULAR Abstract Archive
POS0894 (2024)
SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
Reassuring 15000 pt yrs f/u RA PsA AS https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
EULAR Abstract Archive
RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX)
870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
EULAR Abstract Archive
OP0031 (2024)
COMPARATIVE ANALYSIS OF TNF INHIBITORS & IL17 INHIBITORS IN PSORIATIC ARTHRITIS: CARDIOVASCULAR OUTCOMES signif absolute risk diff 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i https://t.co/fNIiMt4caL. @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
Grappa « difficult to treat and complex to manage» PsA meeting - SLR, Patient & rheumo survey, working on definition eg - fail 1 csDMARD & 2 bDMARDs different MOA @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
PRO-SPIRIT 1100+ PsA Observational study
IXE i= TNFi and JAKi for improving joint dis activity in IXE higher previous b/tsDMARD & less concomitant csDMARDs
IXE & IL-17Ai = faster improvement cDAPSA than IL-12/23i or IL-23i
Abst LBA0002 #EULAR2024 @RheumNow https://t.co/8DbtCQECNN
Aurelie Najm AurelieRheumo ( View Tweet)
EFFICACY & SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSA: WEEK 16 RESULTS FROM A RANDOMIZED, DB,PBO CONTROLLED, MULTICENTER 2b/3 STUDY ACR responses 60:40:20 42% MDA PASI 100 47% ho hum same as others-how many IL17s do we need ? @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
POS0231 Safety of JAKi vs TNFi or IL-17 inhibitors in #PsA & #SpA
Results from a large population-based study show reassuring data, with no increased risk of #CVD, #VTE or certain cancers compared to TNFi or IL-17i
@SteZhao @RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
1200 PsA pts 6 countries IL17is as effective as TNFi and JAK despite more failed bDMARDs and monotherapy & faster onset action than IL23s @RheumNow #EULAR2024 https://t.co/SM5CA7KUvd
Peter Nash drpnash ( View Tweet)
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @RheumNow https://t.co/lk42I7Mn8B
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Cohort from Netherlands 400+ PsA pts IR first bioDMARD
300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi
3year retention rates
12 mo 75% cyclers 80% swappers
24mo 60% cyclers 56% swappers
No difference in treatment failure or DAS28 CRP
#EULAR2024 @RheumNow POS0278 https://t.co/J8ONjVAFqG
Aurelie Najm AurelieRheumo ( View Tweet)
EFFICACY AND SAFETY OUTCOMES OF TAK-279, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS - smells tastes & looks like a Tyk2 - acne signal? @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
